12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alpharadin radium-223 regulatory update

Algeta disclosed in its 2Q12 earnings call that partner Bayer will now submit an NDA to FDA and MAA to EMA for Alpharadin this half instead of mid-year to treat bone metastases in patients...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >